Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Case Report
Case Series
Editorial
Original Article
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Case Report
Case Series
Editorial
Original Article
View/Download PDF

Translate this page into:

Original Article
13 (
2
); 41-49

The Combined Diagnostic Role of Digital Rectal Examination, Prostate Specific Antigen, Transrectal Ultrasound and Transrectal Ultrasound Guided Biopsy to Differentiate Benign Versus Malignant Prostatic Enlargement

Senior resident, Dept of urology, Narayana Medical College, Nellore, India
Senior Resident, Dr Pinnamaneni Siddhartha Institute of Medical Sciences, Andhra Pradesh
Senior Resident, Dept of Urology, Venkateshwara Kidney Centre, Karimnagar, India

*Corresponding Author: Ershad Hussain Galeti Email: dr.ershadhussain@gmail.com

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Abstract

Introduction:

The term prostatomegaly encompasses both Benign Prostatic Hyperplasia and Carcinoma of the Prostate. This study aimed to find a screening tool for the early diagnosis of prostate carcinoma so that that specific treatment can be instituted at an early stage in the Indian population.

Objectives:

To establish the role of digital Rectal Examination (DRE), Prostate-Specific antigen (PSA), transrectal ultrasound (TRUS) and transrectal ultrasound guided biopsy in differentiating benign enlargement from the malignancy of the prostate.

Methods:

This was a prospective observational study conducted over two years in 130 men above 40 years with Lower Urinary Tract Symptoms specifically attributed to prostate problems. Utility of PSA, DRE, TRUS and TRUS guided biopsy for diagnosis of prostate carcinoma were evaluated and compared.

Results:

Among the benign cases, 1.72% had PSA< 4 ng/mL, 86.21% had PSA between > 4 to 10 ng/mL and 12.07% had PSA >10 ng/mL. Among the malignant cases, 9.09% had PSA < 4 ng/mL, 4.55% had PSA between >4 to 10 ng/mL and 86.36% had PSA more than 10 ng/mL. The sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of DRE for diagnosis of malignancy were 54.55%, 98.28%, 92.31%, 85.07% and 86.25%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of TRUS for diagnosis of malignancy were 72.73%, 94.83%, 84.21%, 90.16% and 88.75%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of PSA for diagnosis of malignancy were 90.91%, 22.41%, 30.77%, 86.67% and 41.25%, respectively.

Conclusion:

The proportion of suspicion of malignancy by DRE increased significantly, with an increase in the Gleason score. As the PSA level increases, the chances of biopsy having malignancy also increased significantly. Therefore, it is suggested to do TRUS-guided transrectal Biopsy in patients with abnormal DRE and PSA more than 10 ng/mL

Keywords

Digital rectal examination
hyperplasia
prostate specific antigen
transrectal ultrasound
prostate cancer

Fulltext Views
4

PDF downloads
0
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections